Neomorph Announces First Patient Dosed in Phase 1/2 Trial Evaluating NEO-811 For the Treatment of Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

2026-02-03 - 18:15

Initiation of trial marks first-in-human milestone for Neomorph’s novel molecular glue degrader platform Read More